Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance

Relative Strength Index



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 11 28.8 0.64% 1.75% 25.1% -5.7% 153.2%
SHORT 11 44.5 0.27% 0.38% 16.0% -10.4% -35.1%


Technical Analysis

The relative strength index (RSI) is a momentum indicator developed by noted technical analyst Welles Wilder which compares the magnitude of recent gains and losses over a specified time period to measure speed and change of price movements of a security. It is primarily used to attempt to identify overbought or oversold conditions in the trading of an asset.

Calculation: Relative Strength Index (RSI):
1) RSI = 100 - 100 / (1 + RS);
2) RS = Average Gain / Average Loss;

PROFILE: Ra Pharmaceuticals Inc (RARX)

Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Relative Strength Index

Company Close Change(%) Volume Value Signal
TLGT Teligent 0.42 5.5 1,235,129 42.41 NEUTRAL
ADRO Aduro Biotech 1.48 5 1,056,005 68.59 NEUTRAL
SYRS Syros Pharmaceuticals 8.2 4.9 153,243 60.76 NEUTRAL
MGI Moneygram 2.68 4.7 2,612,033 61.3 NEUTRAL
XENT Intersect Ent 25.17 4.7 1,131,415 60.05 NEUTRAL
FARM Farmer Brothers 13.38 4.4 116,584 42.83 NEUTRAL
TRUP Trupanion Inc 33.32 4.2 261,897 48.31 NEUTRAL
JBLU Jetblue Airways 19.8 3.9 12,375,231 66.94 NEUTRAL
CCRN Cross Country Healthcare 10.85 3.9 684,096 49.65 NEUTRAL
WING Wingstop 93.64 3.7 681,774 61.37 NEUTRAL